Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India’s Generics Fear Backlash From New WHO Counterfeit Definition

This article was originally published in PharmAsia News

Executive Summary

Indian generics makers are wary of a new United Nations definition of what constitutes a counterfeit drug. The firms say the World Health Organization's new definition is being used to erect barriers to generic drugs in the United States, European Union and Japan where drugs are highly regulated. The Indian industry worries the use of the anti-counterfeit program already has led to reviews of Indian manufacturing standards already certified by U.S. FDA. The U.S. legal action against Ranbaxy Laboratories for marketing drugs based on ingredients from unapproved sources is interpreted as increased diligence in ensuring quality. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts